04:48 AM EST, 11/06/2026 (MT Newswires) -- Fusion Antibodies (FAB.L) secured an affinity engineering contract from a listed European global pharmaceutical company, according to a Friday release. The British preclinical antibody discovery company will use its proprietary Rational Affinity Maturation Programme technology to engineer the client's lead antibody under the project, which falls within an existing master services agreement. The project is expected to generate over 45,000 pounds sterling in revenue and be completed in the current financial year.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.